|
Getting your Trinity Audio player ready...
|
By Mary Mwendwa
NAIROBI, KENYA – In a seismic shift in the fight against HIV, the Ministry of Health today announced the roll-out of Lenacapavir, a groundbreaking long-acting injectable that protects against the virus for six months with just a single dose.
Kenya has made history as the first country in East Africa to launch this revolutionary prevention tool, positioning itself at the vanguard of the battle to end the HIV epidemic. The announcement, made by the Cabinet Secretary for Health on Tuesday, heralds a new era for a nation where 41% of new infections occur in young people under 24.
“This is not just a new medicine; it is a discreet, innovative, and practical shield for those who need it most,” the statement read, underscoring the nation’s commitment to protecting its citizens.
Lenacapavir is a form of Pre-Exposure Prophylaxis (PrEP) that works by blocking critical stages of the HIV life cycle, preventing the virus from ever taking hold in the body. Unlike daily pills, which can be challenging for many to adhere to, this injection offers a full six months of protection per dose, translating to just two visits to a clinic per year.
Kenya’s selection in July 2025 as one of only nine countries globally—and the first in East Africa—to introduce the drug was a resounding endorsement of its robust health infrastructure and leadership. Following fast-tracked approvals by the US FDA and the World Health Organization, Kenya’s own Pharmacy and Poisons Board (PPB) gave the green light in January 2026.
The roll-out is being powered by an aggressive procurement strategy. An initial batch of 21,000 starter doses, funded by the Global Fund at a negotiated rate of just Ksh. 7,800 per patient per year, has already arrived. A further 12,000 continuation doses are expected by April to ensure seamless treatment.
In a major boost, the United States Government has committed an additional 25,000 doses, signaling strong international confidence in Kenya’s plan.
“The greatest advantage is the freedom it gives,” a senior official from NASCOP (National AIDS and STI Control Programme) explained. “For a young woman, or a key population, the fear of taking a daily pill due to stigma or simply forgetting is now gone. This is a game-changer.”
The Ministry emphasized that Lenacapavir is not a vaccine or a cure, but a prevention tool for those who are HIV-negative. It is intended to complement, not replace, life-long antiretroviral treatment for the 1.34 million Kenyans currently living with the virus.
The strategy is a phased blitzkrieg beginning in early March. The first wave targets 15 high-priority counties, including the urban epicenters of Nairobi, Mombasa, Kisumu, and Kiambu, as well as key border points like Busia and high-burden areas like Homa Bay and Migori. A second and third phase will subsequently blanket the remaining 32 counties, ensuring nationwide access.
With strengthened distribution channels via KEMSA and robust monitoring tools in place, Kenya is not just introducing a drug; it is scripting a new chapter in the global HIV response. The message from the Ministry is clear: The fight is far from over, but with this new weapon, the endgame has never looked more attainable.
